Royalty Pharma’s $205 Million Acquisition of Zealand Pharma A/S future royalty streams and $85 million of potential commercial milestones for Soliqua® 100/33/ Suliqua® and Lyxumia®/Adlyxin®

Ambrogio Visconti

Goodwin advised Zealand Pharma A/S on the deal This transaction will immediately provide substantial value and secure funding for development of Zealand’s fully-owned product pipeline. Upon…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Author: Ambrogio Visconti

…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here